Țară: Irlanda
Limbă: engleză
Sursă: HPRA (Health Products Regulatory Authority)
Buprenorphine hydrochloride
Le Vet Beheer B.V.
QN02AE01
Buprenorphine hydrochloride
0.3 milligram(s)/millilitre
Solution for injection
POM: Prescription Only Medicine as defined in relevant national legislation
Cats, Dogs
buprenorphine
Neurological Preparations
Authorised
2015-11-27
Health Products Regulatory Authority 20 November 2020 CRN009RQW Page 1 of 5 SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE VETERINARY MEDICINAL PRODUCT Buprefelican Multidose 0.3 mg/ml solution for injection for dogs and cats 2 QUALITATIVE AND QUANTITATIVE COMPOSITION EACH ML CONTAINS: ACTIVE SUBSTANCE: Buprenorphine 0.3 mg (Equivalent to buprenorphine hydrochloride 0.324 mg) EXCIPIENTS: Chlorocresol 1.35 mg For the full list of excipients, see section 6.1. 3 PHARMACEUTICAL FORM Solution for injection. Clear, colourless aqueous solution. 4 CLINICAL PARTICULARS 4.1 TARGET SPECIES Dogs and cats. 4.2 INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES Post-operative analgesia in the dog and cat. Potentiation of the sedative effects of centrally acting agents in the dog. 4.3 CONTRAINDICATIONS Do not administer by the intrathecal or peridural route. Do not use pre-operatively for Caesarean section (see section 4.7). Do not use in known cases of hypersensitivity to the active substance or any of the excipients. 4.4 SPECIAL WARNINGS FOR EACH TARGET SPECIES None. 4.5 SPECIAL PRECAUTIONS FOR USE SPECIAL PRECAUTIONS FOR USE IN ANIMALS Buprenorphine may cause respiratory depression and as with other opioid drugs, care should be taken when treating animals with impaired respiratory function or animals that are receiving drugs that can cause respiratory depression. In case of renal, cardiac or hepatic dysfunction or shock, there may be greater risk associated with the use of the product. Safety has not been fully evaluated in clinically compromised cats. Buprenorphine should be used with caution in animals with impaired liver function, especially biliary tract disease, as the substance is metabolised by the liver and its intensity and duration of action may be affected in such animals. Health Products Regulatory Authority 20 November 2020 CRN009RQW Page 2 of 5 The safety of buprenorphine has not been demonstrated in animals less than 7 weeks of age. Repeat administration earlier than the recommended repeat interval suggested Citiți documentul complet